CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquired Noveprim Group for $392.4 million total consideration (2023 step-up to a 90% controlling interest; initial 49% interest acquired in 2022 for $90.0 million plus up to $5.0 million contingent), a transaction completed in November 2023, structured as cash (step acquisition to controlling interest).
Noveprim Group operates in DSA. Noveprim Group was a leading provider of non-human primates (NHPs) used for biomedical, pharmaceutical and toxicological research purposes. Charles River acquired a 90% controlling interest, having previously taken a 49% equity stake in 2022.
The acquisition strengthens and diversifies the supply chain for our DSA segment. We had previously acquired a 49% equity stake in 2022 for $90.0 million up-front. The total preliminary purchase price for the Noveprim acquisition is $374.8 million.
Advisory firms were not disclosed for this transaction.